Dual treatment combining HER2-targeted therapy (Lapatinib) with the CDK7 inhibitor THZ1 strongly inhibits HER2+ breast cancer cell growth and increases apoptosis in cancer cells that exhibit resistance to HER2-targeted therapies.357. Here, CDK7 is linked to breast carcinoma.